FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies-Reference-Cited by-同舟云学术

FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies

Published:2013-05 Issue:5 Volume:189 Page:1676-1681
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

van Kessel Kim E.M.¹,Kompier Lucie C.¹,de Bekker-Grob Esther W.¹,Zuiverloon Tahlita C.M.¹,Vergouwe Yvonne¹,Zwarthoff Ellen C.¹,Steyerberg Ewout W.¹

Affiliation:

1. Departments of Public Health and Pathology (LCK, TCMZ, ECZ), Erasmus Medical Center, Rotterdam, The Netherlands

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference23 articles.

1. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer;Zuiverloon;Clin Cancer Res,2010

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

3. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation;Almallah;Urology,2000

4. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison;van der Aa;BJU Int,2008

5. Surveillance for bladder cancer: the management of 4.8 million people;Wright;BJU Int,2000

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer;PLOS ONE;2023-02-10

2. New Advances in the Prediction of NMIBC Recurrence by Genetic Biomarkers;Advances in Clinical Medicine;2023

3. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions;Urologic Oncology: Seminars and Original Investigations;2021-01

4. Urinary Biomarkers: Current Status and Future Opportunities;Comprehensive Diagnostic Approach to Bladder Cancer;2021

5. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review;Urologic Oncology: Seminars and Original Investigations;2020-06